Abstract Details

Title An Open-Label, Nonrandomized, Prospective, Multicenter Study To Evaluate the Safety and Tolerability of Glatiramer Acetate 20 mg sc Once Daily in Patients with Severe Relapsing-Remitting Multiple Sclerosis That Have Discontinued Natalizumab after 12 to 18 Months Therapy. Preliminary Results

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 005

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Silvia Rossi, MD	No disclosure on file
Teresa Coelho, MD (Unidate Clinica de Paramoloidose Hospital)	Dr. Coelho has nothing to disclose.
	No disclosure on file
	No disclosure on file
Caterina Motta	Caterina Motta has nothing to disclose.
	No disclosure on file
Valentina De Chiara, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file
Marco Salvetti, MD	Dr. Salvetti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for sanofi. Dr. Salvetti has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen. The institution of Dr. Salvetti has received research support from bms.
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��